Skip to main content

Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor

Publication ,  Conference
De Bono, JS; Fizazi, K; Saad, F; Taplin, M-E; Sternberg, CN; Miller, K; Mulders, P; Chi, KN; Armstrong, AJ; Hirmand, M; Selby, B; Scher, HI
Published in: JOURNAL OF CLINICAL ONCOLOGY
May 20, 2012

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2012

Volume

30

Issue

15

Location

Chicago, IL

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
De Bono, J. S., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., … Scher, H. I. (2012). Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 30). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
De Bono, Johann Sebastian, Karim Fizazi, Fred Saad, Mary-Ellen Taplin, Cora N. Sternberg, Kurt Miller, Peter Mulders, et al. “Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
De Bono JS, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, et al. Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2012.
De Bono, Johann Sebastian, et al. “Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor.” JOURNAL OF CLINICAL ONCOLOGY, vol. 30, no. 15, AMER SOC CLINICAL ONCOLOGY, 2012.
De Bono JS, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, Mulders P, Chi KN, Armstrong AJ, Hirmand M, Selby B, Scher HI. Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2012.

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2012

Volume

30

Issue

15

Location

Chicago, IL

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences